HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study
Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Langue: | anglais |
| Publié: |
May 2026
|
| In: |
Radiation oncology
Year: 2026, Volume: 21, Pages: 1-13 |
| ISSN: | 1748-717X |
| DOI: | 10.1186/s13014-026-02856-3 |
| Accès en ligne: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13014-026-02856-3 |
| Notes sur l'auteur: | Victor Siefert, Joana V. Bettenhausen, Alicia S. Bicu, Ralf Schmidt, Marvin Willam, Miriam Eckl, Florian Stieler, Michael Ehmann, Daniel Buergy, Jens Fleckenstein, Bettina Beuthien-Baumann, Heinz-Peter Schlemmer, Matthias F. Froelich, Stefan O. Schoenberg, Frank A. Giordano, Judit Boda-Heggemann and Constantin Dreher |
| Résumé: | Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during image-guided radiotherapy (IGRT). This study evaluated the feasibility of HyperSight™ CBCT-based muscle assessment in prostate cancer patients and explored the clinical relevance of intratreatment muscle decline. |
|---|---|
| Description: | Im Titel ist TM hochgestellt Online veröffentlicht: 29. Mai 2026 Gesehen am 11.06.2026 |
| Description matérielle: | Online Resource |
| ISSN: | 1748-717X |
| DOI: | 10.1186/s13014-026-02856-3 |